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Tuberculosis remains a major global health problem and efforts to develop a more effec-
tive vaccine have been unsuccessful so far. Targeting antigens (Ags) to dendritic cells 
(DCs) in vivo has emerged as a new promising vaccine strategy. In this approach, Ags 
are delivered directly to DCs via antibodies that bind to endocytic cell-surface receptors. 
Here, we explored DC-specific-ICAM3-grabbing-nonintegrin (DC-SIGN) targeting as 
a potential vaccine against tuberculosis. For this, we made use of the hSIGN mouse 
model that expresses human DC-SIGN under the control of the murine CD11c promoter. 
We show that in  vitro and in  vivo delivery of anti-DC-SIGN antibodies conjugated to 
Ag85B and peptide 25 of Ag85B in combination with anti-CD40, the fungal cell wall 
component zymosan, and the cholera toxin-derived fusion protein CTA1-DD induces 
strong Ag-specific CD4+ T-cell responses. Improved anti-mycobacterial immunity was 
accompanied by increased frequencies of Ag-specific IFN-γ+ IL-2+ TNF-α+ polyfunctional 
CD4+ T cells in vaccinated mice compared with controls. Taken together, in this study 
we provide the proof of concept that the human DC-SIGN receptor can be efficiently 
exploited for vaccine purposes to promote immunity against mycobacterial infections.
Keywords: Dc-specific-icaM3-grabbing-nonintegrin, tuberculosis, vaccine, dendritic cells, ag85B
inTrODUcTiOn
Tuberculosis (Tb) remains one of the leading causes of death worldwide with an estimated 10.4 
million people becoming infected per year (1). Currently, the only available vaccine against Tb 
is Mycobacterium bovis Bacillus Calmette-Guérin (BCG); however, it is only partially effective: it 
provides protection against severe forms of Tb in infants but is unable to prevent the development 
Abbreviations: Mtb, Mycobacterium tuberculosis; Tb, tuberculosis; DCs, dendritic cells; CLR, C-type lectin receptor; Ag, 
antigen; DC-SIGN, DC-specific-ICAM3-grabbing-nonintegrin; BMDCs, bone-marrow-derived dendritic cells; GM-CSF, 
granulocyte-macrophage colony-stimulating factor; KLRG1, killer cell lectin-like receptor G1.
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of adult pulmonary Tb, the most prevalent form of the disease (2, 
3). Thus, there is an urgent need to develop novel vaccine strate-
gies that are safe and effective and can prevent all forms of Tb in 
different age groups.
Protection against Tb has long been attributed to CD4+ T cells 
and in particular to IFN-γ-secreting T-helper 1 (Th1) cells (4). 
However, recent knowledge suggests that additional pathways 
could also play important roles in vaccine-induced immunity 
against Tb. In this respect, IL-23-driven Th17 cells were shown 
to contribute to the generation of antigen (Ag)-specific Th1 cells 
and the protection against Mycobacterium tuberculosis (Mtb) 
following vaccination with BCG (5) and proved to be key effec-
tor cells in different parenteral and mucosal subunit-based Tb 
vaccine models (6–9). Furthermore, BCG- or environmental 
mycobacteria-induced regulatory T  cells (Tregs) have been 
proposed as one of the reasons for the delayed onset of adaptive 
immunity observed in Tb and to limit the generation of steri-
lizing immunity (10, 11).
Dendritic cells (DCs) are specialized Ag-presenting cells that 
play a central role in initiating and regulating adaptive immunity 
(12). Owing to their potent Ag presentation capacity and ability 
to generate distinct T-cell responses, efficient and specific deliv-
ery of Ags to DCs is the cornerstone for generating Ag-specific 
effector and memory cells against tumors or pathogens (13, 14). 
Administration of autologous DCs exogenously loaded with 
tumor-Ags was the first DC-based vaccine developed (15). Since 
then, a few other ex vivo DC vaccines have been generated and 
tested in clinical trials. However, they show low clinical responses 
and have high production costs, making them unavailable for 
mass vaccination in developing countries which hold the highest 
Tb burden (16, 17). To overcome these limitations, a new concept 
of directly targeting endocytic receptors on DCs by Ag-coupled 
antibodies or glycosylated molecules was developed as a more 
effective strategy. Moreover, this type of approach allows the 
targeting of specific DC subsets while maintaining the natural 
environment of the cells (13, 17, 18).
C-type lectin receptors (CLRs) are an important family of 
calcium-dependent lectins that are structurally related through 
the expression of at least one carbohydrate recognition domain 
(CRD). Many CLRs are abundantly but also uniquely expressed 
on the surface of specific DC subsets, where they mediate 
pathogen recognition and internalization of Ags (19, 20). Due 
to these properties, CLRs represent ideal candidates for target-
ing purposes. Pioneer studies in this field focused on the use of 
antibodies against DEC-205 (CD205) conjugated to OVA to elicit 
resistance against OVA-modified pathogens and tumors (21–23). 
However, expression of DEC-205 in humans is not only restricted 
to DCs (24), thus carrying the possibility of inadvertently target-
ing other cell types. In contrast, human DC-specific-ICAM3-
grabbing-nonintegrin (DC-SIGN, CD209) is predominantly 
present on the surface of immature monocyte-derived DCs and at 
lower levels on mature monocyte-derived DCs and macrophages 
in the skin, mucosal tissues, and secondary lymphoid organs 
(25, 26). Contrary to humans, who only express DC-SIGN, mice 
possess eight DC-SIGN homologs in their genome. Sequence 
analysis of the DC-SIGN receptor family in humans and mice has 
demonstrated that it underwent substantial divergence between 
both species. Thus, none of the murine DC-SIGN homologs pre-
sents the same functions (glycan specificity, internalization and 
intracellular trafficking, intercellular adhesion and signaling) as 
the human DC-SIGN, making the study of this receptor in mice 
challenging (27, 28). To circumvent this issue, we generated and 
made use of the hSIGN mouse model which expresses human 
DC-SIGN under the control of the murine CD11c promoter and 
thus expresses the human receptor predominantly on DCs (29). 
We previously demonstrated that DC targeting via injection of 
anti-DC-SIGN antibodies into hSIGN mice induces strong and 
durable Ag-specific CD4+ and CD8+ T-cell responses capable 
of mediating protection against infection with OVA-expressing 
Listeria monocytogenes (30). Thus, this study provided powerful 
evidence that targeting of DC-SIGN in vivo results in protection 
against intracellular pathogens.
Targeting of DCs via anti-CLR antibodies is also known to 
induce tolerance unless an adjuvant is co-delivered (21, 31, 32). 
Given that adjuvants have the ability of skewing the type of 
response upon vaccination by the induction of different T-helper 
subsets, selection of the proper adjuvant system is critical for 
targeting approaches. In the current study, we aimed to develop a 
new vaccine strategy against Mtb based on targeting DCs through 
the use of anti-human-DC-SIGN antibodies conjugated to Ag85B, 
a subdominant but highly immunogenic protein from Mtb (33), 
and peptide 25 (P25) (covering the amino-acid residues 240–254) 
of Ag85B, a major Th1 epitope (34). We provide here the proof 
of concept that immunization with anti-DC-SIGN antibodies 
conjugated to Mtb Ags can effectively induce anti-mycobacterial 
immunity in  vivo. Furthermore, we characterize the type of 
response elicited by different adjuvant systems.
MaTerials anD MeThODs
Mice
hSIGN mice were described previously (29) and P25ktk mice (35) 
were obtained from Jackson Laboratories. P25ktk mice were fur-
ther crossed to CD45.1 mice. Sex- and age-matched mice between 
12 and 18 weeks were used in all experiments. All animals were 
bred and maintained under specific pathogen-free conditions 
at the animal facility of TWINCORE, Center for Experimental 
and Clinical Infection Research (Hannover, Germany) or the 
Helmholtz Center for Infection Research (HZI, Braunschweig, 
Germany). All animal experiments were approved by the 
Veterinary Institute of LAVES (Lower Saxony State Office for 
Consumer Protection and Food Safety, permit numbers: 12/0732 
and 17/2472) considering the German Animal Welfare Act.
conjugation of anti-Dc-sign antibodies
The conjugated monoclonal anti-DC-SIGN (αDC-SIGN) 
antibodies (clone: AZN-D1, IgG1) to Ag85B protein (αDC-
SIGN:Ag85B) and Ag85B240–254 peptide (P25) (αDC-SIGN:P25) 
were prepared as previously described (25). Briefly, the antibodies 
or an isotype control antibody were conjugated to the different 
proteins using the crosslinking agent sulfosuccinimidyl-4-(N-
maleimidomethyl)-cyclohexane-1-carboxylate according to the 
manufacturer’s protocol (sulfo-SMCC; Pierce).
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Flow cytometry
The following antibodies and reagents were purchased from 
Thermo Fisher Scientific/eBioscience: anti-CD4 (GK1.5), 
anti-CD4 (RM4–5), anti-CD45.1 (A20), anti-IFN-γ (XMG1.2), 
anti-CD11c (N418), anti-MHC-II (M5/114.15.2), anti-CD86 
(GL1), anti-IL-17A (eBio17B7), anti-CD44 (IM7), anti-IL-2 
(JESG-SH4), anti-TNF-α (MP6-XT22), anti-IL-10 (JES5-16E3), 
anti-FoxP3 (FJK-16s), anti-KLRG1 (2F1), anti-CD127 (A7R34), 
and Brefeldin A. Cellular aggregates were excluded by gating 
singlets using SSC-A versus SSC-W. Dead cells were excluded 
by LIVE/DEAD® Fixable Aqua Dead (Thermo Fisher Scientific/
Invitrogen) cell staining. For intracellular cytokine staining, 
cells were fixed with 0.5% Paraformaldehyde (Roth) overnight 
and permeabilized in PBA-S buffer (0.5% Saponin (Roth) and 
0.25% BSA (Roth) in PBS). Intranuclear FoxP3 staining was per-
formed using the Fixation/Permeabilization kit (Thermo Fisher 
Scientific/eBioscience) according to manufacturer’s instructions. 
Data acquisition was performed using a LSRII (BD, Biosciences) 
or a CyAn™ ADP (Beckman Coulter) flow cytometer. Data 
analysis was performed with FlowJo software (Tree Star).
adjuvants
Zymosan was purchased from Sigma-Aldrich and prepared as 
indicated by the manufacturer’s instructions. The non-toxic 
CTA1-DD adjuvant was kindly provided by Prof. N. Lycke 
(Department of Clinical Immunology, Göteborg University, 
Sweden).
In Vitro T-cell Proliferation assay
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-
derived bone-marrow-derived dendritic cells (BMDCs) were 
generated from BM  cells using a standard protocol. Briefly, 
BM cells were cultured for 7 days in complete RPMI [10% FCS 
(Biochrom), 10 mM Hepes (Gibco), 50 µM β-mercaptoethanol 
(Gibco), 100 U/mL penicillin, and 100 μg/mL streptomycin 
(Biochrom)] supplemented with 5% culture supernatant of a 
GM-CSF-producing cell line (36). On day 7, 25.000 BMDC/well 
were incubated with αDC-SIGN:Ag85B or αDC-SIGN:P25 at the 
indicated concentrations in the presence of αCD40 (1  µg/mL; 
clone 1C10) for 24 h, washed and incubated in a 1:8 ratio with CD4+ 
T cells obtained from the spleen and lymph nodes of P25ktk mice, 
enriched by negative magnetic selection using the Dynabeads™ 
Untouched™ Mouse CD4 Cells isolation kit (Thermo Fisher 
Scientific/Invitrogen) following the manufacturer’s instructions. 
After enrichment, cells were labeled with the CellTrace Violet 
Cell Proliferation Kit (Thermo Fisher Scientific/Invitrogen). The 
purity of enrichment was checked by flow cytometry and resulted 
higher than 85%. Co-cultures were then incubated in complete 
RPMI medium for 4 days at 37°C in 96-well round bottom plates 
(Greiner Bio-One/Cellstar). At day 4, cells were stimulated with 
PMA (0.1 µg/mL) and ionomycin (1 µg/mL). After 2 h of stimula-
tion, Brefeldin A was added for additional 2 h before staining for 
flow cytometric analysis.
In Vitro stimulation of BMDcs
GM-CSF-derived BMDCs were generated as mentioned above 
and stimulated with αCD40 (1 µg/mL) or different concentrations 
of CTA1-DD or zymosan for 24 h followed by staining for surface 
activation markers for flow cytometric analysis. LPS (100  ng/
mL; E. coli Serotype 055:B5; Merck/Sigma Aldrich) was used as 
positive control. Culture supernatants were collected and ELISA 
assays were performed to determine IL-6, IL-23, IL-1β, and IL-10 
production following the manufacturer’s instructions (R&D 
System).
In Vivo T-cell Priming
2 × 106 CellViolet-labeled congenic CD45.1+ CD4+ P25ktk T cells 
were adoptively transferred intravenously (i.v.) into WT or hSIGN 
mice. One day later, mice were immunized with αDC-SIGN:P25 
(2  μg/mouse), αDC-SIGN:Ag85B (2 μg/mouse) or isotype 
control (2 μg/mouse) in the presence of αCD40 (10 μg/mouse), 
CTA1-DD (10 μg/mouse) or zymosan (200 μg/mouse). Five days 
after transfer, spleens were removed and stimulated with PMA 
(0.1 µg/mL) and ionomycin (1 µg/mL). After 2 h of stimulation, 
Brefeldin A was added for additional 2 h before staining for flow 
cytometric analysis.
Vaccination with αDc-sign antibodies
WT or hSIGN mice were immunized with αDC-SIGN:P25 (10 μg/
mouse) in combination with αCD40 (10 μg/mouse), CTA1-DD 
(10 μg/mouse) or zymosan (200 μg/mouse) intraperitoneally 
(i.p.) three times with a 2-week interval between each immuniza-
tion. Unvaccinated controls received saline solution (PBS).
experimental infections
Vaccinated mice were challenged 42 days after the first immu-
nization by i.v. administration of 2 × 106 colony-forming units 
(CFUs) of M. bovis BCG overexpressing Ag85B (M. bovis 
BCG-Ag85B), kindly provided by Dr. Joel Ernst (NYU School 
of Medicine, USA). M. bovis BCG-Ag85B was grown at 37°C in 
Middlebrook 7H9 broth (BD Bisociences) supplemented with 10% 
Middlebrook oleic acid–albumin–dextrose–catalase (OADC) 
enrichment medium (Difco Laboratories), 0.05% of Tween 80 
(Roth) and 0.002% glycerol (Roth). After 5 days of infection, mice 
were sacrificed and spleens were collected in sterile bags (Nasco) 
containing 1 mL of WTA buffer [0.01% Tween-80 and 0.05% BSA 
(Roth)] and mechanically disrupted. Viable bacterial loads were 
determined by plating serial dilutions onto Middlebrook 7H11 
agar (BD Biosciences) supplemented with 10% OADC (Difco 
Laboratories) and 0.5% glycerol (Roth). Colonies were counted 
after 2 to 3 weeks of incubation at 37°C.
statistical analysis
Data analysis was performed using GraphPad Prism Software 5.0. 
Statistics were calculated using one-way or two-way ANOVA as 
indicated in figure legends. P-Values were considered significant 
as follows: *p < 0.05, **p < 0.01, and ***p < 0.001.
resUlTs
Targeting Mtb ags to Dcs via Dc-sign 
induces strong cD4+ T-cell responses
We previously showed that αDC-SIGN antibodies conjugated 
to OVA induce strong and persistent Ag-specific CD4+ and 
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CD8+ T-cell responses which promote rapid clearance of OVA-
expressing Listeria monocytogenes infection (30). Thus, we 
proposed DC targeting via DC-SIGN as a promising strategy for 
vaccination protocols against intracellular pathogens. In order to 
determine whether this strategy could be effective against Mtb, we 
conjugated αDC-SIGN antibodies to Ag85B (αDC-SIGN:Ag85B) 
and Ag85B240–254 peptide (P25) (αDC-SIGN:P25) and tested their 
capacity to induce T-cell activation in  vitro. To achieve this, 
BMDCs were prepared from WT or hSIGN mice and pulsed with 
different concentrations of αDC-SIGN:Ag85B or αDC-SIGN:P25 
in the presence of αCD40 as an adjuvant. The capacity of antibody-
targeted WT and hSIGN BMDCs to promote T-cell responses 
was then evaluated by co-culturing them with CellViolet-labeled 
CD4+ T cells purified from P25ktk mice, carrying a transgenic 
TCR that specifically reacts to P25 in the context of MHC class-II 
presentation (35). After 4  days of co-culture, cell proliferation 
and cytokine production were measured by flow cytometry as 
parameters of T-cell activation. Both αDC-SIGN:Ag85B and 
αDC-SIGN:P25 in combination with αCD40 were able to pro-
mote Ag presentation by BMDCs generated from hSIGN but not 
WT mice, as evidenced by their ability to induce the proliferation 
of CD4+ P25ktk T cells (Figures 1A,C). Moreover, both conju-
gated antibodies also promoted the production of IFN-γ in the 
proliferating CD4+ P25ktk T cells, indicating that targeting DCs 
via DC-SIGN not only results in Ag presentation to CD4+ T cells 
in vitro but also in efficient cytokine production (Figures 1B,D).
We next determined whether targeting Ags to DCs via human 
DC-SIGN also leads to enhanced T-cell responses in  vivo. To 
this aim, we adoptively transferred CellViolet-labeled congenic 
CD45.1+ CD4+ P25ktk T cells into WT or hSIGN-recipient mice 
and 1 day later immunized them with either αDC-SIGN:Ag85B, 
αDC-SIGN:P25, isotype or vehicle control in combination with 
αCD40. Four days after immunization, mice were sacrificed and 
the proliferation as well as cytokine production of the transferred 
T cells was determined by flow cytometry after gating on CD45.1+ 
CD4+ T cells in the splenic cell population. Treatment of hSIGN 
mice with either αDC-SIGN:Ag85B or αDC-SIGN:P25 led to 
significant expansion and IFN-γ production of the transferred 
CD45.1+ CD4+ P25ktk T cells. In contrast, in WT mice only a 
marginal expansion of Ag-specific CD4+ T  cells was observed 
upon immunization, indicating that the conjugated Ags were 
preferentially delivered to DCs via the DC-SIGN receptor. Similar 
results were obtained after the administration of an isotype 
antibody in combination with αCD40 while the vehicle control 
failed to induce T-cell proliferation (Figures 1E,F). Thus, in vitro 
and in  vivo targeting of DCs through αDC-SIGN  antibodies 
conjugated to Mtb Ags efficiently promotes Ag presentation, 
proliferation and IFN-γ production by CD4+ T cells.
cTa1-DD and Zymosan induce Dc 
activation and cytokine Production
In recent years, it has been demonstrated that vaccine-induced 
immunity against Mtb not only depends on the generation of 
Th1 cells but also on other T-helper subsets such as Th17 cells 
(5, 7). Thus, adjuvant selection for new vaccine candidates 
is critical. Cholera toxin (CT) is a potent cyclic adenosine 
monophosphate (cAMP)-based adjuvant which can  effectively 
prime Th17  cells via stimulation of CD11b+ DCs (37). Unfor-
tunately, CT is not approved for human vaccination due to its 
high toxicity. To solve this problem, a fusion protein between 
the A1 catalytic domain of CT and two immunoglobulin-
binding D regions from Staphylococcus aureus protein A called 
CTA1-DD was developed with the same adjuvant activity of CT 
but without its toxicity (38). Through a different mechanism, 
the Saccharomyces cerevisiae cell-wall component zymosan also 
promotes strong Th17 cell responses using TLR-dependent and 
-independent pathways (39–41). Therefore, we evaluated the 
ability of these adjuvants to broaden the spectrum of T-helper 
responses elicited by our αDC-SIGN antibodies. We first tested 
whether CTA1-DD and zymosan were able to induce DC matu-
ration and cytokine production. For this, we generated BMDCs 
from WT and hSIGN mice and incubated them with αCD40 
(1 µg/mL), LPS (100 ng/mL) and different concentrations of 
CTA1-DD and zymosan. After 24 h, upregulation of the activa-
tion marker CD86 was measured by flow cytometry and cytokine 
production by ELISA. CTA1-DD only mildly enhanced CD86 
surface expression by WT and hSIGN DCs (Figures 2A,B) but 
was able to increase the percentage of CD86hi MHC-IIhi DCs of 
both genotypes at the highest concentration tested (Figure 2C). 
Moreover, CTA1-DD also promoted the secretion of IL-6, IL-23 
and IL-1β in a dose-dependent manner while inducing low levels 
of IL-10 (Figures  2D–G). In contrast, zymosan significantly 
upregulated CD86 expression (Figures  2A,B) and increased 
the percentage of CD86hi MHC-IIhi DCs of both genotypes at all 
concentrations tested (Figure  2C). Overall, zymosan induced 
the highest cytokine levels (Figures 2D–G). Surprisingly, αCD40 
proved a poor stimulus for DC activation, at least at the studied 
concentration (Figures  2A–G). As expected, the TLR4 agonist 
LPS served as positive control promoting DC maturation and 
cytokine production (Figures  2A–G). In addition, no marked 
differences were observed between WT and hSIGN BMDCs in 
regard to their ability to upregulate CD86 expression and secrete 
pro- and anti-inflammatory cytokines, demonstrating that human 
DC-SIGN expression does not affect DC function/activation. 
Taken together, these results indicate that both CTA1-DD and 
zymosan are capable of promoting DC activation and cytokine 
production.
administration of αDc-sign:P25 with 
cTa1-DD or Zymosan Promotes  
effective T-cell Priming
We next determined whether CTA1-DD and zymosan in 
combination with the αDC:SIGN conjugates could also induce 
specific T-cell responses in vivo. Given the similar performance 
observed in our preliminary results, we opted to focus on the 
αDC-SIGN:P25 antibody for further experiments. To investigate 
this, we performed adoptive transfer assays as described above 
using CellViolet-stained congenic CD45.1+ CD4+ P25ktk T cells 
transferred into WT or hSIGN-recipient mice. One day later, we 
injected αDC-SIGN:P25 in the presence of CTA1-DD or zymosan. 
Expansion and cytokine production by the transferred cells was 
evaluated 4 days later by flow cytometry. Immunization of hSIGN 
FigUre 1 | In vitro and in vivo targeting of Mycobacterium tuberculosis antigens to DC via DC-specific-ICAM3-grabbing-nonintegrin (DC-SIGN) induces strong 
CD4+ T-cell responses. (a–D) CellViolet-labeled CD4+ P25ktk T cells were co-cultured with WT or hSIGN BMDC targeted with increasing doses of (a,B) αDC-
SIGN:Ag85B or (c,D) αDC-SIGN:P25 in the presence of αCD40 (1 µg/mL). After 4 days of co-culture (a,c) in vitro proliferation of CD4+ T cells and (B,D) 
intracellular IFN-γ production were determined by flow cytometry after restimulation with PMA/ionomycin. Bar graphs represent the (a,c) number of proliferating 
CellViolow CD4+ cells and (B,D) number of proliferating IFN-γ+ CellViolow CD4+ cells. Error bars represent SD of triplicate wells from one of three experiments. 
**p < 0.01 and ***p < 0.001; two-way ANOVA with Bonferroni’s post hoc test. (e,F) CellViolet-labeled CD45.1+ CD4+ P25ktk T cells were adoptively transferred into 
WT or hSIGN mice. One day later, mice were immunized with (e) αDC-SIGN:Ag85B (2 µg), (F) αDC-SIGN:P25 (2 µg) or an isotype control (2 µg) (e) or vehicle (F) in 
the presence of αCD40 (10 µg). Four days post-immunization (e,F) in vivo cell proliferation and intracellular IFN-γ production were determined by flow cytometry in 
splenocytes after ex vivo restimulation with PMA/ionomycin. Shown are representative flow cytometry plots depicting the percentage of IFN-γ+ CellViolow among 
CD45.1+ CD4+ T cells. Bar graphs represent the total number of proliferating CD45.1+ CellViolow CD4+ cells and percent of proliferating IFN-γ+ CD45.1+ CellViolow 
among all live CD4+ T cells. Error bars represent SD of 3–5 mice per group from one of two experiments. *p < 0.05, **p < 0.01, and ***p < 0.001; one-way ANOVA 
with Bonferroni’s post hoc test.
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FigUre 2 | CTA1-DD and zymosan induce DC activation and cytokine production. (a–g) WT or hSIGN BMDC were treated with αCD40 (1 µg/mL) and different 
concentrations of CTA1-DD and zymosan. LPS (100 ng/mL) was used as a positive control. After 24 h stimulation, (a–c) CD86 and MHC-II surface expression was 
determined by flow cytometry and (D) IL-6, (e) IL-23, (F) IL-1β and (g) IL-10 production by ELISA. (a) Representative histograms from one of three independent 
experiments. (B) Bar graphs represent mean fluorescence intensity (MFI) of CD86 and (c) percent of CD86hi MHC-IIhi among CD11c+ cells. Error bars represent SD 
of triplicate wells from one of three experiments.
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but not WT mice with αDC-SIGN:P25 plus either CTA1-DD or 
zymosan significantly induced expansion and IFN-γ production 
of the transferred CD45.1+ CD4+ P25ktk T cells (Figures 3A–C). 
However, only zymosan was able to significantly enhance IL-17A 
production by the transferred CD4+ T cells (Figure 3D). Thus, 
targeting DC-SIGN using a P25-conjugated αDC-SIGN antibody 
co-delivered with CTA1-DD or zymosan promotes the generation 
and proliferation of Ag-specific Th1 cells. Furthermore, zymosan 
can, in addition, slightly prime Th17 cells.
Vaccination with αDc-sign:P25 Plus 
αcD40, cTa1-DD, or Zymosan Does not 
induce Th17 cells but Prevents  
the expansion of Tregs
Having demonstrated the potential of αDC:SIGN antibodies to 
target DC and induce strong Ag-specific T-cell responses, we 
decided to evaluate the αDC-SIGN:P25 antibody in a standard 
vaccination protocol. For this, we immunized WT or hSIGN 
FigUre 3 | Administration of αDC-SIGN:P25 with CTA1-DD or zymosan promotes T-cell priming. (a–D) CellViolet-labeled CD45.1+ CD4+ P25ktk T cells were 
adoptively transferred into WT or hSIGN mice. One day later, mice were immunized with αDC-SIGN:P25 (2 µg) plus CTA1-DD (10 µg) or zymosan (200 µg). Four 
days post-immunization (a,B) in vivo cell proliferation and intracellular (a,c) IFN-γ and (a,D) IL-17A production were determined by flow cytometry in splenocytes 
after ex vivo restimulation with PMA/ionomycin. (a) Representative flow cytometry plots depicting the proliferation and percentage of IFN-γ+ (upper panels) or 
IL-17A+ (lower panels) CellViolow among CD45.1+ CD4+ T cells. Bar graphs represent the (B) total number of proliferating CD45.1+ CellViolow CD4+ cells and percent 
of proliferating (c) IFN-γ+ or (D) IL-17A+ CD45.1+ CellViolow among all live CD4+ T cells. Error bars represent SD of three mice per group from one of two 
experiments. *p < 0.05, **p < 0.01, and ***p < 0.001; two-way ANOVA with Bonferroni’s post hoc test.
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mice i.p. at days −42, −28, and −14 prior to M. bovis BCG-Ag85B 
infection with αDC-SIGN:P25 (10 µg) plus either αCD40 (10 µg), 
CTA1-DD (10 µg) or zymosan (200 µg). As control group, mice 
were treated with vehicle (PBS). At day 0, mice were infected i.v. 
with 2 × 106 M. bovis BCG-Ag85B, a strain that overexpresses 
Ag85B. Five days later, bacterial loads and intracellular cytokine 
production after ex vivo restimulation with the cognate peptide 
P25 were determined in spleens (Figure 4A). Contrary to our 
short-term vaccination experiments, we could not detect any 
differences in bacterial burden nor a significant increase in the 
percentage of P25-specific IL-17A-producing CD4+ T  cells in 
hSIGN mice vaccinated with the αDC-SIGN:P25 antibody plus 
any of the adjuvants used (Figures 4B,C). These results seem to 
indicate that in the tested settings the αDC-SIGN:P25 antibody 
is unable to promote a persistent Th17 response and does not 
impact bacterial growth. On the other hand, limited vaccine 
efficacy is thought to be linked to the expansion of Tregs upon 
BCG administration (10). Therefore, vaccine candidates should 
avoid induction of anti-inflammatory immune responses. Thus, 
we also evaluated whether vaccination with αDC-SIGN:P25 plus 
αCD40, CTA1-DD or zymosan could increase the population 
of IL-10-producing T cells or FoxP3+ Tregs in spleens. hSIGN 
mice vaccinated with CTA1-DD showed a significant increase 
in the percentage of P25-specific IL-10+ CD4+ T cells only com-
pared with unvaccinated controls (Figure 4D). Yet, we could not 
detect differences in the percentage of IL-10-producing CD4+ 
T  cells in any of the other experimental groups (Figure  4D). 
Regarding Tregs, hSIGN mice vaccinated in the presence of 
zymosan showed a significant decrease in FoxP3+ CD4+ T cells 
compared with PBS-treated controls (Figure 4E). None of the 
FigUre 4 | Vaccination with αDC-SIGN:P25 plus αCD40, CTA1-DD or zymosan does not induce Th17 cells but prevents the expansion of regulatory T cells.  
(a) Experimental scheme. WT or hSIGN mice were vaccinated i.p. at days −42, −28, and −14 with vehicle (PBS) or αDC-SIGN:P25 (10 µg) plus αCD40 (10 µg), 
CTA1-DD (10 µg) or zymosan (200 µg). At day 0, mice were challenged i.v. with 2 × 106 Mycobacterium bovis BCG-Ag85B. Five days later, bacterial burden, 
intracellular cytokine production after ex vivo restimulation with P25 (30 µg/mL), and FoxP3 expression were determined in spleen. (B) Graph represents the 
logarithmic transformation of the number of colony-forming units (CFUs) per spleen of vaccinated mice. (c–e) Graphs represent percent of (c) P25-specific IL-17A+, 
(D) IL-10+ and (e) FoxP3+ among CD4+ T cells of vaccinated mice. Each symbol represents an individual mouse and results are pooled from two experiments with 
4–5 mice per group. *p < 0.05 and **p < 0.01; two-way ANOVA with Bonferroni’s post hoc test.
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other adjuvant systems employed showed differences in this 
population compared with controls (Figure  4E), suggesting 
that Tregs are not significantly expanded during our vaccina- 
tion approach.
Vaccination With αDc-sign:P25 Plus 
αcD40, cTa1-DD, or Zymosan induces 
Pro-inflammatory cytokine Production
T-helper 1 cells have a preponderant role in mounting protec-
tive immune responses against Tb (42, 43). Polyfunctional 
T  cells, defined as able to produce multiple pro-inflammatory 
cytokines, such as IFN-γ, IL-2 and TNF-α, have been identified 
as correlates of protection in the mouse model of Tb (44, 45). 
We therefore tested the ability of the αDC-SIGN:P25 antibody in 
combination with αCD40, CTA1-DD or zymosan to induce this 
type of responses after vaccination and ex vivo restimulation with 
P25 (Figure 5A). hSIGN mice vaccinated with αDC-SIGN:P25 
plus αCD40 only showed a mild increase in the percentage of 
Ag-specific IFN-γ and IL-2-producing cells among CD44+ CD4+ 
T cells (Figures 5B,C). In the case of CTA1-DD, we could observe 
a significant increase in the percentage of IFN-γ, IL-2 and TNF-
α-producing cells among CD44+ CD4+ T  cells in hSIGN mice 
compared with WT and unvaccinated controls (Figures 5B,D). 
Moreover, we could observe a slight but significant increase in 
the percentage of Th1-type polyfunctional CD4+ T cells, which 
co-secrete IFN-γ, IL-2 and TNF-α and are indicators of vaccine-
induced immunity against Tb (Figures  5B,D). Concerning 
zymosan, the generation of IFN-γ, IL-2 and TNF-α-producing 
cells among CD44+ CD4+ T cells was significantly enhanced in 
hSIGN mice with respect to WT and unvaccinated controls and 
percentages of Th1-polyfunctional T cells were also significantly 
higher (Figures 5B,E). It is important to note that we obtained the 
strongest immune responses with zymosan. Taken together, these 
results suggest that DC targeting via αDC-SIGN:P25 in combina-
tion with CTA1-DD or zymosan induces immunity against Mtb 
via the generation of Th1-type cells and polyfunctional CD4+ 
T cells.
FigUre 5 | Vaccination with αDC-SIGN:P25 plus αCD40, CTA1-DD or zymosan induces pro-inflammatory cytokine production. (a) Experimental scheme. WT or 
hSIGN mice were vaccinated i.p. at days −42, −28, and −14 with vehicle (PBS) or αDC-SIGN:P25 (10 µg) plus αCD40 (10 µg), CTA1-DD (10 µg) or zymosan 
(200 µg). At day 0, mice were challenged i.v. with 2 × 106 Mycobacterium bovis BCG-Ag85B. Five days later, mice were sacrificed and splenocytes were isolated 
and stained for intracellular cytokine production after ex vivo restimulation with P25 (30 µg/mL). (B) Representative flow cytometry plots depicting the percentage of 
IFN-γ+ (upper panels), IL-2+ (middle panels) and TNF-α+ (lower panels) among CD44+ CD4+ T cells. (c–e) Graphs represent percent of IFN-γ+, IL-2+, TNF-α+ and 
polyfunctional (IFN-γ+ IL-2+ TNF-α+) among CD44+ CD4+ T cells of mice vaccinated with (c) αCD40, (D) CTA1-DD and (e) zymosan. Each symbol represents an 
individual mouse and results are pooled from two experiments with 4–5 mice per group. *p < 0.05, **p < 0.01, and ***p < 0.001; two-way ANOVA with Bonferroni’s 
post hoc test.
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FigUre 6 | αDC-SIGN:P25 plus zymosan generates hyperactivated CD4+ T cells. (a) Experimental scheme. WT or hSIGN mice were vaccinated i.p. at days −42, 
−28, and −14 with vehicle (PBS) or αDC-SIGN:P25 (10 µg) plus αCD40 (10 µg), CTA1-DD (10 µg) or zymosan (200 µg). At day 0, mice were challenged i.v. with 
2 × 106 Mycobacterium bovis BCG-Ag85B. Five days later, mice were sacrificed and blood was isolated and stained for killer cell lectin-like receptor G1 (KLRG1) 
and CD127 surface expression. (B) Representative flow cytometry plots depicting percentage of KLRG1+ CD127+ and KLRG1+ CD127− among CD4+ T cells. (c,D) 
Graphs represent percent of (c) KLRG1+ CD127+ and (D) KLRG1+ CD127− among CD4+ T cells of vaccinated mice. Each symbol represents an individual mouse 
and results are pooled from two experiments with 4–5 mice per group. **p < 0.01 and ***p < 0.001; two-way ANOVA with Bonferroni’s post hoc test.
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αDc-sign:P25 Plus Zymosan generates 
hyperactivated cD4+ T cells
In recent years, several reports have shown that the state of dif-
ferentiation and polarization of Th1 cells is important to deter-
mine their ability to control Mtb infection. Indeed, it has been 
demonstrated that less-polarized CD4+ T cells are more beneficial 
in terms of long-term protection against this pathogen (46–49). 
Thus, we analyzed the CD4+ T-cell memory and activation profile 
generated by the αDC-SIGN:P25 antibody in combination with 
the different adjuvants according to the experimental scheme in 
Figure  6A. hSIGN mice vaccinated with αDC-SIGN:P25 plus 
zymosan showed a significant increase in the percentage of both 
effector memory (KLRG+ CD127+) (Figures 6B,C) and terminally 
differentiated effector (KLRG1+ CD127−) CD4+ T  cells in the 
blood (Figures 6B,D). On the contrary, αCD40 and CTA1-DD 
did not induce an increase in those populations. These results 
correlate with the fact that zymosan proved to be the strongest 
stimulus for the activation of CD4+ T cells and indicate that this 
adjuvant induces a rapid response upon infection with a tendency 
toward a more differentiated phenotype.
DiscUssiOn
The development of an effective vaccine against Tb remains an 
unresolved public health issue. Of the many vaccine candidates 
in the clinical trial pipeline, so far none has proven to provide 
protection against infection or sterilizing immunity. In this study, 
we explored the potential of DC targeting via human DC-SIGN as 
a novel vaccine strategy against Tb. Using anti-human-DC-SIGN 
antibodies conjugated to Ag85B and P25 we could demonstrate 
that the CLR DC-SIGN can be efficiently targeted in DCs which 
results in the proliferation and IFN-γ production of P25-specific 
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CD4+ T cells in vitro and in vivo. We also demonstrated that the 
type of T-cell response elicited by the anti-DC-SIGN antibodies 
and its strength is influenced by the adjuvant system used for 
the delivery. Finally, we show that anti-mycobacterial immunity 
based on Th1 and polyfunctional CD4+ T cells is achieved in a 
vaccination protocol with the anti-DC-SIGN antibody conju-
gated to P25.
We here provide evidence that human DC-SIGN is a potent 
targeting receptor that has the ability of inducing strong 
immune responses. First, in our in vitro results we show that low 
amounts of anti-DC-SIGN antibodies (0.001–0.1 µg/mL) are 
enough to induce Ag presentation and secretion of IFN-γ. This 
represents an advantage to ex vivo DC vaccines, where not only 
higher amounts of protein are needed but also the generation 
of autologous DCs is time consuming and expensive. Second, 
we also demonstrate that the presence of human DC-SIGN on 
DCs is sufficient to promote Ag presentation and the induction 
of an immune response upon immunization with anti-DC-SIGN 
antibodies in  vivo. Though some response can be observed in 
WT and isotype-treated mice, probably due to the binding of 
the antibodies to Fc receptors or other receptors in an unspecific 
manner, the response in hSIGN mice is much stronger with 
high percentages of IFN-γ-producing cells. This corresponds 
with the fact that the IgG1 murine AZN-D1 antibody used for 
our targeting purposes has been shown to induce fast clathrin-
dependent internalization of DC-SIGN upon binding and to 
direct Ags to late endosomal compartments facilitating efficient 
Ag presentation (50). Third, we have previously demonstrated 
that conventional DCs are the main target of the anti-DC-SIGN 
antibodies in this kind of vaccination approach. hSIGN mice 
express the human DC-SIGN receptor under the control of the 
CD11c promoter. Though CD11c is not exclusively expressed on 
DCs, we have previously shown that the transgene is predomi-
nantly expressed on CD11chigh SiglecH− conventional DCs and 
can be detected in spleen, lymph nodes and lungs of hSIGN 
mice via immunohistochemistry (29, 30). Furthermore, the 
complementarity determining regions of AZN-D1 were grafted 
onto a human IgG2/IgG4 composite antibody with the objective 
of generating a humanized antibody which was later conjugated 
to the model Ag keyhole limpet hemocyanin (KLH) resulting in 
100-fold more efficient targeting of human DCs compared with 
ex vivo Ag loading (51). Hence, extrapolating DC-SIGN target-
ing into a human vaccine could be an achievable aim. In this 
regard, it would be interesting to evaluate which subsets of DCs 
are the main targets for this vaccination approach.
Our results demonstrate that DC-SIGN targeting can 
generate P25-specific Th1 and polyfunctional T  cells without 
significantly inducing IL-10-producing T cells or expanding the 
Treg population. Protective immunity against Mtb is known to 
rely on IFN-γ-secreting Th1 cells. The fact that Th1 cells play a 
central role in protection against Tb is based on several factors: 
(i) mice lacking CD4+ T cells, IFN-γ and IL-12 signaling or T-bet 
are highly susceptible to infection (4); (ii) individuals with genetic 
deficiencies in IFN-γ and IL-12 signaling are unable to control 
mycobacterial infections (52); (iii) HIV patients co-infected with 
Tb have increased risk of developing active disease (53). Apart 
from Th1 cells, other potential correlates of protection have been 
identified in the mouse model of Tb. The frequency and quality 
of polyfunctional CD4+ T  cells was shown to correlate with 
protective immunity when comparing five different Tb vaccine 
 models (live-attenuated, subunit, viral vectored, plasmid DNA 
and combination vaccines) (44). In contrast, Tregs have been 
shown to negatively influence vaccine efficacy (10). In this respect, 
our targeting strategy has the added advantage of avoiding the 
induction of these types of counteractive immune responses.
T-helper 17 cells have also been shown to provide protection 
against Tb either by recruiting Th1 cells to the infected lung or 
even by IFN-γ-independent mechanisms (5, 7, 54). Zymosan is a 
strong Th17-inducer stimulus, used in different IL-17-dependent 
experimental models such as arthritis (55). Upon treatment with 
zymosan, BMDCs were shown to promote the differentiation of 
naïve T cells into IL-17-producing cells in vitro and to support 
the induction of experimental autoimmune encephalomyelitis 
(EAE) symptoms in mice (40). In contrast, CTA1-DD was 
designed as a mucosal adjuvant capable of inducing powerful 
antibody responses (38). We demonstrated that both of these 
adjuvants were able to induce the activation of BMDCs and 
the secretion of IL-6, IL-23, and IL-1β, all important cytokines 
necessary for the induction of Th17 responses (56, 57). The 
fact that we could not observe differences in the percentages of 
P25-specific Th17 cells after vaccination could be due to the low 
amounts of IL-17A-producing cells generally observed in our 
experimental system. Likewise, in our previous reports M. bovis 
BCG-infected mice showed only marginal Th17 percentages at 
21 days post-infection (58). This suggests that in our settings this 
T-cell subset is underrepresented, probably due to the restricted 
flora in our animal facility (SPF conditions). In this sense, there 
is evidence that the diversity of the intestinal microbiota and 
the presence of specific segmented filamentous bacteria can 
influence the amount of intestinal Th17 cells in mice from the 
same strain but from different facilities (59, 60). Thus, testing 
our vaccination system in mice with a more diverse microbiota 
would be important to define the importance of Th17 for anti-
DC-SIGN-mediated immunity.
Several studies suggest that the activation status as well as 
the migration capacity of Th1  cells themselves is important to 
generate long-term protection. Distinct phenotypes based on the 
expression of programmed death-1 (PD-1) and killer cell lectin-
like receptor G1 (KLRG1) were described among CD4+ T cells 
during Mtb infection. Thus, PD-1+ CD4+ T cells exhibit superior 
proliferation capacity though produce lower levels of IFN-γ, 
while KLRG1+ CD4+ T cells secrete high amounts of IFN-γ but 
show a terminally differentiated phenotype with reduced ability 
to proliferate (46). These KLRG1+ T cells express CX3CR1, are 
mainly found in the vasculature, and have diminished capacity to 
migrate into the lung parenchyma in contrast to KLRG1− PD-1+ 
CXCR3+ cells which are mainly found in this tissue (48). As a 
consequence of their less-differentiated profile, KLRG1− cells 
are able to persist and maintain anti-mycobacterial immunity 
after Mtb infection (47, 48, 61). In our experimental approach, 
the combination of the anti-DC-SIGN antibody conjugated to 
P25 with zymosan resulted in the strongest immune response in 
terms of cytokine production and also showed increased percent-
ages of total KLRG1+ CD4+ T cells 5 days post-infection. These 
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results suggest that zymosan induces a rapid increase of terminally 
activated cells but whether this is consequence of the vaccination 
or the ongoing infection remains unclear. Also, whether zymosan 
or CTA1-DD can generate Ag-specific KLRG1− CD4+ T  cells 
with the ability to persist in the long term is yet to be evaluated. 
Therefore, it would be interesting to assess the memory profile of 
the P25-specific CD4+ T cells generated upon vaccination with 
anti-DC-SIGN antibodies previous to challenge.
In spite of generating P25-specific CD4+ T cells against Mtb, we 
were unable to detect differences in the bacterial burden between 
unvaccinated and vaccinated mice. In our approach, we chal-
lenged the immunized mice with Ag85B-overexpressing BCG 
strain as a mycobacterial infection model. The rational behind 
this choice was based on the fact that Ag85B is expressed at lower 
levels in BCG compared to Mtb, where this protein is one of the 
major components of the bacterial culture filtrate (62). However, 
this model has a limitation in the sense that it is cleared much 
faster than the reference BCG Pasteur strain (data not shown). 
Hence, aerosol challenge with virulent Mtb would provide a 
better indication of whether DC-SIGN targeting has protec-
tive capacity against infection. In this sense, it would also be 
interesting to test whether the intranasal immunization route 
influences the type of response elicited by our anti-DC-SIGN 
antibodies. The mucosal administration of M. bovis BCG has 
shown to provide superior protection and favor the generation 
of lung-resident memory T  cells (63, 64). Furthermore, upon 
intranasal administration of CTA1-DD in combination with 
QuilA-containing immune-stimulating complexes (ISCOMs) 
and the fusion protein Ag85B-ESAT-6, this adjuvant was shown 
to provide protection against Tb in the lung (38, 65, 66). Another 
advantage of the use of an antibody-based targeting strategy is 
the possibility of coupling different Ags to them. A broader range 
of Mtb epitopes can be covered in this manner, either CD4+ or 
CD8+, and therefore result in an improved immune response. 
CD8+ T-cell responses have also been shown to mediate pro-
tection through their ability to secrete high amounts of IFN-γ 
and TNF-α and kill Mtb-infected macrophages (67, 68). Thus, 
mucosal administration of anti-DC-SIGN antibodies conjugated 
to different CD4+ and CD8+ epitopes plus CTA1-DD or zymosan 
could support the long-term generation of Mtb-specific Th1, 
Th17 and CD8+ T  cells along with other desirable memory 
T-helper subsets.
To conclude, we demonstrate here the potential of targeting 
human DC-SIGN to generate Ag-specific immune responses 
against Mtb. Even though further studies are needed in order 
to optimize this vaccination approach, we conclude that CLR 
targeting is a powerful tool that can be exploited to modulate 
immune responses and design novel vaccine strategies against 
global-health-threatening intracellular pathogens.
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